Relcovaptan

Relcovaptan (SR-49059) is a non-peptide inhibitor of the antidiuretic hormone (vasopressin) receptor, selective for the V1a subtype. It has shown positive initial results in tests against Raynaud's disease, dysmenorrhoea, and tocolysis, although it is not yet approved for clinical use.